WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and ...
Apellis just got a J-code for reimbursement for its lead therapy from CMS. The company saw revenue climb 473% year over year in the second quarter. Apellis has two marketed products, Syfovre and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results